Genmab A/S (NASDAQ:GMAB) Expected to Announce Quarterly Sales of $443.42 Million

Equities research analysts predict that Genmab A/S (NASDAQ:GMABGet Rating) will post $443.42 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Genmab A/S’s earnings, with estimates ranging from $411.89 million to $470.40 million. Genmab A/S reported sales of $319.48 million during the same quarter last year, which indicates a positive year-over-year growth rate of 38.8%. The business is scheduled to report its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Genmab A/S will report full year sales of $1.83 billion for the current financial year, with estimates ranging from $1.77 billion to $1.95 billion. For the next fiscal year, analysts anticipate that the company will post sales of $2.31 billion, with estimates ranging from $2.12 billion to $2.55 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Genmab A/S.

Genmab A/S (NASDAQ:GMABGet Rating) last issued its quarterly earnings results on Wednesday, February 16th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.13 by $0.04. The firm had revenue of $402.74 million for the quarter, compared to analyst estimates of $387.16 million. Genmab A/S had a return on equity of 10.90% and a net margin of 26.34%.

GMAB has been the topic of several recent research reports. Cowen started coverage on Genmab A/S in a research report on Monday, May 2nd. They set a “market perform” rating on the stock. Zacks Investment Research lowered shares of Genmab A/S from a “hold” rating to a “sell” rating in a research report on Thursday, January 20th. Morgan Stanley reduced their price target on shares of Genmab A/S to $29.00 and set an “underweight” rating on the stock in a research note on Tuesday. Cowen started coverage on Genmab A/S in a report on Monday, May 2nd. They set a “market perform” rating and a $38.00 price objective for the company. Finally, JPMorgan Chase & Co. dropped their target price on Genmab A/S from 3,200.00 to 3,100.00 in a research report on Friday, February 25th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $425.38.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Liberty Wealth Management LLC raised its position in Genmab A/S by 285.6% in the third quarter. Liberty Wealth Management LLC now owns 671 shares of the company’s stock worth $28,000 after acquiring an additional 497 shares during the period. Cordasco Financial Network lifted its holdings in Genmab A/S by 40.8% during the 3rd quarter. Cordasco Financial Network now owns 915 shares of the company’s stock valued at $40,000 after buying an additional 265 shares in the last quarter. Covestor Ltd purchased a new position in shares of Genmab A/S in the 4th quarter valued at $37,000. Bessemer Group Inc. lifted its position in Genmab A/S by 50.3% during the 4th quarter. Bessemer Group Inc. now owns 1,156 shares of the company’s stock worth $46,000 after acquiring an additional 387 shares during the period. Finally, Captrust Financial Advisors increased its stake in shares of Genmab A/S by 23.2% in the 3rd quarter. Captrust Financial Advisors now owns 1,414 shares of the company’s stock valued at $62,000 after purchasing an additional 266 shares in the last quarter. Institutional investors own 5.92% of the company’s stock.

Shares of NASDAQ:GMAB traded up $1.02 during trading on Thursday, reaching $30.40. The stock had a trading volume of 936,748 shares, compared to its average volume of 658,937. The firm’s fifty day moving average is $34.81 and its 200 day moving average is $36.35. Genmab A/S has a 52 week low of $27.42 and a 52 week high of $49.07. The stock has a market cap of $19.98 billion, a price-to-earnings ratio of 52.09, a P/E/G ratio of 1.37 and a beta of 0.98.

Genmab A/S Company Profile (Get Rating)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Further Reading

Get a free copy of the Zacks research report on Genmab A/S (GMAB)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Genmab A/S (NASDAQ:GMAB)

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with's FREE daily email newsletter.